Statistically Significant Final Three-Year OS Benefit observed for Herlystic-Treated Patients in Ph 2b Pulmonary Metastatic Osteosarcoma Trial

“With final three-year overall survival data now in hand, we are working diligently to complete regulatory submissions in the U.S., U.K., Europe and Australia to enable early market access to the therapy,” said Dr. Craig Eagle, Chief Medical Advisor and Director of OS Therapies. “Given that we have full alignment on the clinical trial design of the confirmatory Phase three trial across international regulatory agencies, we are preparing to submit a Clinical Trial Authorisation (CTA) to the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) as the precursor to trial initiation. Commencing the Phase 3 study is a prerequisite to being granted Accelerated Approval of a Biologics License Application (BLA) by the U.S. Food & Drug Administration (FDA), and Conditional Marketing Authorisation Applications (CMAAs) by MHRA, the European Medicines Agency (EMA) and the Australian Therapeutic Goods Administration (TGA).”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib